Advanced Therapeutics Manufacturing accelerates in Stockholm

Photo: Henrik Trygg, mediabank.visitstockholm.com

A new report from Invest Stockholm on Advanced Therapeutics Manufacturing and Life Science in the Stockholm region shows that the sector has grown by 66% in the past four years. Synergies between the local tech and pharma industries are expected to further enhance Stockholm’s competitiveness and growth in the future.

The Stockholm-Uppsala region is home to both global companies and an ever-increasing number of specialist startups, and Stockholm is fast becoming a leading international hub for firms wishing to establish and expand their advanced therapeutics manufacturing facilities. But what is it that underpins the phenomenal growth we are seeing?

“The report makes it very clear that the thriving Stockholm-Uppsala life science cluster benefits hugely from a long tradition of collaboration between the public sector, industry and academia. In the region’s many hubs for innovation and entrepreneurship, transparent structures and a sense of common purpose enable local governments, life science companies and universities to work together to forge a brighter future,” says Ylva Hultman, Head of Life Science at Invest Stockholm.

As the report shows, the region’s success can be explained by factors including: a diverse talent pool, stable operating conditions, exceptional physical infrastructure, world leading environmental credentials and an attractive business environment.

Strong growth in the life science sector can be partly explained by an increase in demand due to the ongoing pandemic, but it’s important to note that the sector had already seen 28% growth in 2019.

“Exports for the sector are now valued at US$13.6bn and represent 10% of the total value of Sweden’s exports. We are very happy to see that advanced manufacturing is becoming one of the strongest sectors in the Stockholm region,” says Hultman.

For the European biotechnology sector in 2020, there were 74 listings for Nasdaq Nordic, compared to 43 for London and 12 for Switzerland. In the coming decade it is predicted that Sweden and the Stockholm region will be among the best places in the world in which to invest.

Download the report and learn more about the work being done to fuel the sector by organisations like Business Sweden, Invest Stockholm, the pharmaceutical trade association Lif and SwedenBIO, alongside universities in Stockholm and Uppsala. The report features a detailed overview of the sector by Professor Johan Rockberg from the Royal Institute of Technology, and Catarina Flyborg, Vice President of Cell and Gene Therapy at Cytiva. It also includes case studies from life science companies AstraZeneca, Cambrex, Cytiva, Galderma, Pharmadule Morimatsu, and Valneva, all based in the Stockholm region.

For updated investment cases and business opportunities in the Stockholm region, please contact:
Ylva Hultman, Head of Life Science Investment Promotion, Invest Stockholm
+46 (0)70-472 80 65, ylva.hultman@stockholm.se